REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Vesting of RSUs and PDMR Dealing

MaxCyteAnnouncement

26/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250326:nRSZ1474Ca&default-theme=true

RNS Number : 1474C  MaxCyte, Inc.  26 March 2025

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

Vesting of RSUs and PDMR Dealing

 

Rockville, Maryland - 26 March 2025: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT),
a leading, cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and commercialization of
next-generation cell-based therapeutics, announces that on 18 March 2025, as
per a filing lodged with the U.S. Securities and Exchange Commission, that
XXX,XXX shares of previously granted restricted stock units ("RSUs") vested to
Douglas Swirsky, Chief Financial Officer of the Company ("Vesting").
Contemporaneously, 6,939 of the newly vested shares were sold to cover
withholding tax due upon the vesting.  Such "sale to cover" was automatically
effected to satisfy withholding tax liabilities and does not represent a
discretionary trade by Mr. Swirsky. The 20,313 new shares of Common Stock were
issued pursuant to the Company's existing block admission facility and were
sold by Mr. Swirsky at a price range between $3.140 and $3.215 per Common
Stock ("Sale"). The sold shares represent approximately 2.2% of Mr.
Swirsky's total equity and option holdings in the Company's stock capital,
respectively.

 

Following the Vesting and Sale, Mr. Swirsky holds 13,374 shares of Common
Stock representing 2.2% of the issued stock capital of the Company. Mr.
Swirsky holds a further 725,000 options over Common Stock, 98,437 RSUs, and
68,750 Performance Stock Units.

 

The information in the tables below is provided in accordance with the
requirements of the UK Market Abuse Regulation.

 

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 25 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or disposables;
and software protocols, all supported by a robust worldwide intellectual
property portfolio. By providing our partners with the right technology
platform, as well as scientific, technical and regulatory support, we aim to
guide them on their journey to transform human health. Learn more at
maxcyte.com
(https://www.globenewswire.com/Tracker?data=VdrNaYkwAJ9WwG9klgnWyIDNt8so7DJ9m0UVbRM4Jqv4j2Onf7xqyPaP3WzEDCJdjepOLjZUJ-DdiYkNM1ychWPeAmxgbHDduMtKyD6ZXn-jZusQ5ZyAg1mGKv_aVAQWmKgW9SH0FAafQVbv7G9Ix7M5Mgor9Xmc31sNOyEBLb7fZvv4FP72ZahgFZcZfj_t5mlPESPybUyLI788Bue5RjivI0geiSeEJqXXwQ8udI7H3uyVAEQSQKUjKzyUOPn0kRcpfcJM1m7LkqDRWFTBL3JzSUdvMr9R-R1Gg7hdjW8P0liao_wIfjH9yP7OpN4-0n1KWk-9NYDZUoVp6ItI7IwjbTGsiqbY3T-K58uS1BdiH9z1H_zWi-yVC3QPhAz2xWgGzzjkQi_j0D8Sujatpcr-YKtYB0RyxFiFhd982jsFOrOwmBKlFrIUhajbNhm-NoCB64R0sdOAgVB0LRcfn-FYbsoXidzUrk6v2RY_-85M8rxH1PoC8HU_n1W6_K3NKVljlnNaInkdnXBN3Omm_U7HWMc7RZ-jLBAXnRBSUjdZ_0PGOoGMBQWqqBSdKqvvTAWrzvkxIacSr0-aaafBwqdPVNLye1OX47d3cwzaGFs=)
and follow us on X
(https://www.globenewswire.com/Tracker?data=isCtCg65p0CbNVJ6AXxT1tBwAw1GYIU1nFnKfhEBarClpI5bHEgVLfmx9ekBJpFQoT2xrEiqNEbQqIb-_fSo4Fudy1TV6kz1pW2v128nvnSebExAn9P4JpL1yYEmFXpcUlZRCUIqtyGzuXQAmWXnIPbvqqvItCyw4XcbpgXofSQVXAjhxnk-z0Cg0hASJ7nKSP4rPBAKDLhbylwzpBLC9moUXYzV_01dKZRSRM9M7Y9dIreV9QAuZPJo0YwZKX4RQPTUzGaerE12X0GIQ9N3gFGLUWIFgpvc2GUQ4YoLwDAAPcX_i8BGLdzZ8XaS3_ApWSYHud6dJiJk-f8cAO7fHfaCzz9H84KUz-AviJ02XhyWGyE5KyeaYkSUYT8tqXflheF5czNOEVhTSylqBgzwuzaXz-8oGq0-QLHu4lINnW39cIUPzJqdjV1gqbUO9iSJRX2-LOAj1H7csvOfXZMeBK3gyIU8axWOc_H7JclLXHuGhydAPVZrVQ3MCjqu5QP2_Y9whANJKrq5NJFUZNouniLUHRdvx0uzHGRQ37Aoy2jUkpPnEVeXK6kH6mA-k_fO3wQ9BQyTb5wylU_0C4UhcApt9uLtFwSxwZmpH_qfe7s=)
and LinkedIn
(https://www.globenewswire.com/Tracker?data=e9IYJ1lCMc9J2oG-gd_VlF0X2m4E3xuwc_YdxT-4G5U0xkhH1crIN_6KiarTslVgjv885_VjnDlT_qRCOyBgK9r3xG5IgpfJhVYAMGJiRUmUTCj_SDYLxlAhGbbpmnltyD8FAlhv2b84ExZAQ3JMUtAJru_HHsTzAUE_HNooIi_eXuJbnqyP4XEpAttSWy6prCTV4Oa2nPYH-m5_8sy0LyIvXeO_GV0JQnmuWCKlABA6jgCmEjk3mSMCkL87VXvDR_CL8bAFM6o1IgMzM7gnyzp6YDCFWTA79bgpF7oMa8PRgnPrdW04PrfFuM-_VzkqOJdXPv_tj-xgrLGIyr4rWQy1yavkmjNX0lNtgAgbhmMcuu_QrWl5OGwJ3l5GgnO5iF8cLgUGjoyVoxN4N8j9y-9_fYMu-0ojzOfd0J3vBbZ_mDbxdbH39RGjp6ntpsOHuNs5pQ9LhdDUiy1MoZits932aeexiVpphNXifpJdzZz_i67sWSdt6K2iFvO41XxmhAX_kLpLy56KBvTKq8yiuan59oFcYvuSWz1lWwXdVxS-VdKcMPIJKgz2yv5oA_teHUef-TvmpyRMgKomYYYdkiQgMoQC-QQGGjii1kXUsmUeznyNlhiwajXMIdJKH4CgvRk1jXfNYcqdH95tiFNuiA==)
.

 

MaxCyte Contacts:

 

 US IR Adviser

 Gilmartin Group                               +1 415-937-5400

 David Deuchler, CFA                           ir@maxcyte.com (mailto:ir@maxcyte.com)

 Nominated Adviser and Joint Corporate Broker

 Panmure Liberum                               +44 (0)20 7886 2500

 Emma Earl / Freddy Crossley

 Corporate Broking

 Rupert Dearden

 UK IR Adviser                                 +44 (0)203 709 5700

 ICR Healthcre                                 maxcyte@icrhealthcare.com (mailto:maxcyte@icrhealthcare.com)

 Mary-Jane Elliott

 Chris Welsh

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Douglas Swirsky

 2    Reason for the notification

 a)   Position/status                                              Chief Financial Officer

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         MaxCyte Inc.

 b)   LEI                                                          54930053YHXULRFCU991

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Common stock of $0.01 each

      Identification code                                          US57777K1060

 b)   Nature of the transaction                                    Acquisition of common stock following vesting of RSUs

 c)   Price(s) and volume(s)                                                         RSUs:

                                                                                     Exercise Price(s)  Volume(s)
                                                                                     N/A                20,313

 d)   Aggregated information

      - Aggregated volume                                          20,313

      - Price                                                      N/A

 e)   Date of the transaction                                      17 March, 2025

 f)   Place of the transaction                                     US Stock Exchange, Nasdaq

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Douglas Swirsky

 2    Reason for the notification

 a)   Position/status                                              Chief Financial Officer

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         MaxCyte Inc.

 b)   LEI                                                          54930053YHXULRFCU991

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Common stock of $0.01 each

      Identification code                                          US57777K1060

 b)   Nature of the transaction                                    Sale of common stock to satisfy withholding tax liabilities as a condition of

                                                            vesting of RSUs

 c)   Price(s) and volume(s)

                                                                   Price(s)                                 Volume
                                                                   $3.1400                                  153
                                                                   $3.1450                                  30
                                                                   $3.1500                                  427
                                                                   $3.1550                                  74
                                                                   $3.1600                                  941
                                                                   $3.1650                                  49
                                                                   $3.1700                                  1676
                                                                   $3.1750                                  37
                                                                   $3.1800                                  904
                                                                   $3.1850                                  103
                                                                   $3.1900                                  902
                                                                   $3.1950                                  62
                                                                   $3.2000                                  497
                                                                   $3.2050                                  166
                                                                   $3.2100                                  664
                                                                   $3.2150                                  254

 d)   Aggregated information

      - Aggregated volume                                          6,939

      - Price                                                      $3.1793

 e)   Date of the transaction                                      18 March, 2025

 f)   Place of the transaction                                     US Stock Exchange, Nasdaq

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHDBGDXDXDDGUU